We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.17B
AUM Growth
+$164M
Cap. Flow
+$76.2M
Cap. Flow %
6.49%
Top 10 Hldgs %
32.39%
Holding
149
New
25
Increased
54
Reduced
51
Closed
11

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
2
CI icon
Cigna
CI
+$11.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$11.1M
4
VTRS icon
Viatris
VTRS
+$10.5M
5
CELG
Celgene Corp
CELG
+$8.17M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12M
2
UNH icon
UnitedHealth
UNH
+$11M
3
ALGN icon
Align Technology
ALGN
+$9.05M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.45M
5
IART icon
Integra LifeSciences
IART
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Industrials 0.76%
3 Technology 0.15%
4 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
1
Elevance Health
ELV
$80.9B
$50.8M 4.33%
213,527
+32,284
+18% +$7.48M
ALGN icon
2
Align Technology
ALGN
$12.7B
$44.8M 3.82%
131,058
-30,330
-19% -$9.05M
CELG
3
DELISTED
Celgene Corp
CELG
$42.3M 3.61%
532,800
+98,400
+23% +$8.17M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$42M 3.58%
263,217
+15,447
+6% +$2.36M
ILMN icon
5
Illumina
ILMN
$28.2B
$39.4M 3.36%
144,918
+14,081
+11% +$3.58M
ABT icon
6
Abbott
ABT
$175B
$34.7M 2.96%
568,850
+3,850
+0.7% +$233K
MDT icon
7
Medtronic
MDT
$106B
$34.4M 2.93%
401,881
+44,881
+13% +$3.75M
TDOC icon
8
Teladoc Health
TDOC
$1.7B
$33.1M 2.82%
570,110
+54,416
+11% +$2.66M
EW icon
9
Edwards Lifesciences
EW
$49.4B
$29.9M 2.55%
616,980
+25,500
+4% +$1.19M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.5B
$28.4M 2.42%
164,933
+13,211
+9% +$2.16M
BSX icon
11
Boston Scientific
BSX
$65.4B
$26.8M 2.29%
820,596
+124,596
+18% +$3.76M
HUM icon
12
Humana
HUM
$48B
$25.8M 2.2%
86,850
+3,150
+4% +$922K
DXCM icon
13
DexCom
DXCM
$29.6B
$25.7M 2.19%
1,083,588
-341,972
-24% -$7.25M
UNH icon
14
UnitedHealth
UNH
$387B
$23.7M 2.02%
96,729
-45,861
-32% -$11M
DHR icon
15
Danaher
DHR
$144B
$21.6M 1.84%
246,429
+18,573
+8% +$1.65M
CI icon
16
Cigna
CI
$74.5B
$21.5M 1.83%
126,234
+68,584
+119% +$11.9M
COR icon
17
Cencora
COR
$59.9B
$20.4M 1.74%
238,853
+23,675
+11% +$2.08M
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
$20.3M 1.73%
163,730
+32,340
+25% +$3.78M
CNC icon
19
Centene
CNC
$32.8B
$20.1M 1.71%
326,494
+86,454
+36% +$4.99M
SYK icon
20
Stryker
SYK
$123B
$20.1M 1.71%
118,770
+5,470
+5% +$920K
SUPN icon
21
Supernus Pharmaceuticals
SUPN
$2.79B
$19.5M 1.67%
326,600
+37,800
+13% +$1.96M
BDX icon
22
Becton Dickinson
BDX
$43.6B
$19.5M 1.66%
83,245
+31,995
+62% +$7.12M
VTRS icon
23
Viatris
VTRS
$20.1B
$18.2M 1.55%
502,350
+268,400
+115% +$10.5M
HRC
24
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$15.7M 1.34%
179,689
+21,770
+14% +$1.93M
BAX icon
25
Baxter International
BAX
$11.7B
$15.5M 1.32%
210,000
-6,000
-3% -$423K
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2018 Portfolio in Review

As of Q2 2018, Bellevue Group held 149 positions worth $1.17B, up 16% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group deployed $76.2M of net new capital in Q2 2018, opening 25 new positions and adding to 54 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Incyte, an estimated $12M trimmed.

  • Bellevue Group's largest Q2 2018 buy was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q2 2018, an estimated $11.9M increase.
  • Bellevue Group's biggest Q2 2018 reduction was Incyte, cutting an estimated $12M.
  • Bellevue Group fully exited Perrigo in Q2 2018, selling an estimated $2.75M.
  • Bellevue Group's ten largest holdings make up 32% of its $1.17B portfolio in Q2 2018.
  • Bellevue Group opened 25 new positions and closed 11 in Q2 2018.
  • Bellevue Group's portfolio value rose 16% quarter-over-quarter to $1.17B.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.